ePrivacy and GPDR Cookie Consent by TermsFeed Generator

Detail of the clinical trial

Title of the trial An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD- 1/L1 and VEGF-Targeted Therapies
EudraCT number 2019-003444-72
Protocol number MK-6482-005
Sponsor Merck Sharp & Dohme LLC, 126 East Lincoln Ave.,P.O.BOX 2000,Rahway, New Jersey 07065, United States of America
Indications Oncology
Diagnosis Renal Cell Carcinoma
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Year of receiving the request to Institute (SÚKL) 2020
Date of approval by Institute (SÚKL) 20.5.2020
Date of approval by EC 30.4.2020
Date of initiation CT in ČR 27.7.2020
Date of ending CT in ČR
Sites Fakultní nemocnice Hradec Králové,Klinika onkologie a radioterapie,Sokolská 581, Hradec Králové,50005
Masarykův onkologický ústav, Klinika komplexní onkologické péče,Žlutý kopec 7 ,Brno,65653
Fakultní nemocnice Olomouc,Onkologická klinika, I. P. Pavlova 6,Olomouc, 77520
Fakultní nemocnice Ostrava ,Klinika onkologická ,17.listopadu 1790,Ostrava-Poruba,70852
Fakultní nemocnice Královské Vinohrady,Klinika radioterapie a onkologie,Šrobárova 50,Praha 10,100 34

‹‹ Back to list